- Docket Number:
- Issued by:
Guidance Issuing OfficeCenter for Devices and Radiological Health
Document issued on: June 20, 2014
This document supersedes “Guidance for Industry and FDA Staff – Criteria for Significant Risk Investigations of Magnetic Resonance Diagnostic Devices” issued on July 14, 2003.
On June 20, 2014 this document was edited to amend a table on specific absorption rate (SAR) and make minor formatting and contact updates.
For questions regarding this document, contact Jana Delfino, Ph.D., at 301-796-6503, or by e-mail at firstname.lastname@example.org.
U.S. Department of Health and Human Services
Food and Drug Administration
Center for Devices and Radiological Health
Magnetic Resonance and Electronic Products Branch
Division of Radiological Health
Office of In Vitro Diagnostics and Radiological Health
You may submit electronic comments and suggestions at any time for Agency consideration to http://www.regulations.gov. Submit written comments to the Division of Dockets Management, Food and Drug Administration, 5630 Fishers Lane, Room 1061, (HFA-305), Rockville, MD 20852. When submitting comments, please refer to the exact title of this guidance document. Comments may not be acted upon by the Agency until the document is next revised or updated.
Additional copies are available from the Internet. You may also send an e-mail request to CDRH-Guidance@fda.hhs.gov to receive a copy of the guidance. Please use the document number 793 to identify the guidance you are requesting.
Criteria for Significant Risk Investigations of Magnetic Resonance Diagnostic Devices - Guidance for Industry and Food and Drug Administration Staff
This guidance describes the device operation conditions for magnetic resonance diagnostic devices that FDA considers significant risk for the purposes of determining whether a clinical study requires Agency approval of an Investigation Device Exemption (IDE). Magnetic resonance diagnostic devices are class II devices described under 21 CFR 892.1000. The product codes for these devices are:
- LNH Magnetic Resonance Imaging System
- LNI Magnetic Resonance Spectroscopic System
FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidances means that something is suggested or recommended, but not required.
Studies of Magnetic Resonance Diagnostic Devices
If a clinical study is needed to demonstrate substantial equivalence, i.e., conducted prior to obtaining 510(k) clearance of the device, the study must be conducted under the IDE regulation (21 CFR Part 812). FDA believes that a magnetic resonance diagnostic device used under any one of the operating conditions listed below is a significant risk device as defined in 21 CFR 812.3(m)(4) and, therefore, that studies involving such a device do not qualify for the abbreviated IDE requirements of 21 CFR 812.2(b). In addition to the requirement of having an FDA-approved IDE, sponsors of significant risk studies must comply with the regulations governing institutional review boards (21 CFR Part 56) and informed consent (21 CFR Part 50).
Significant Risk Magnetic Resonance Diagnostic Devices
You should consider the following operating conditions when assessing whether a study may be considered significant risk:
- main static magnetic field
- specific absorption rate (SAR)
- gradient fields rate of change
- sound pressure level
Generally, FDA deems magnetic resonance diagnostic devices significant risk when used under any of the operating conditions described below.
Main Static Magnetic Field
|Population||Main static magnetic
field greater than (tesla)
|adults, children, and infants aged > 1 month||8|
|neonates i.e., infants aged 1 month or less||4|
Specific Absorption Rate (SAR)
equal to or greater than:
|whole body||averaged over||15||>4|
If you have questions about significant risk criteria related to local SAR, you may wish to contact FDA.
Gradient Fields Rate of Change
Any time rate of change of gradient fields (dB/dt) sufficient to produce severe discomfort or painful nerve stimulation
Sound Pressure Level
Peak unweighted sound pressure level greater than 140 dB.
A-weighted root mean square (rms) sound pressure level greater than 99 dBA with hearing protection in place.
These criteria apply only to device operating conditions. Other aspects of the study may involve significant risks and the study, therefore, may require IDE approval regardless of operating conditions. See the guidance entitled "Significant Risk and Nonsignificant Risk Medical Device Studies" for further discussion.
After FDA determines that the device is substantially equivalent, clinical studies conducted in accordance with the indications reviewed in the 510(k), including clinical design validation studies conducted in accordance with the quality systems regulation, are exempt from the investigational device exemptions (IDE) requirements. However, such studies must be performed in conformance with 21 CFR 56 and 21 CFR 50.
You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-2020-D-0957.